Guillermo Garcia Manero

Summary

Affiliation: The University of Texas M. D. Anderson Cancer Center
Country: USA

Publications

  1. pmc Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 108:3271-9. 2006
  2. ncbi request reprint Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1060-6. 2008
  3. ncbi request reprint Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 109:3214-8. 2007
  4. ncbi request reprint A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas M D Anderson Cancer Center Houston, TX 77030, USA
    Leuk Lymphoma 48:283-9. 2007
  5. ncbi request reprint Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia
    Yasuhiro Oki
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:899-906. 2007
  6. ncbi request reprint Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
    Andres O Soriano
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2302-8. 2007
  7. ncbi request reprint Biphenotypic acute leukaemia: a case series
    Ahmed Aribi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston TX 77030, USA
    Br J Haematol 138:213-6. 2007
  8. ncbi request reprint The role of decitabine in the treatment of myelodysplastic syndromes
    Ehab Atallah
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Expert Opin Pharmacother 8:65-73. 2007
  9. ncbi request reprint Effect of cytarabine and decitabine in combination in human leukemic cell lines
    Taichun Qin
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4225-32. 2007
  10. ncbi request reprint Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Elias Jabbour
    Department of Leukemia and, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2991-5. 2007

Detail Information

Publications104 found, 100 shown here

  1. pmc Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 108:3271-9. 2006
    ..In summary, this combination of epigenetic therapy in leukemia was safe and active, and was associated with transient reversal of aberrant epigenetic marks...
  2. ncbi request reprint Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1060-6. 2008
    ..Increased histone acetylation was observed at all doses. Antioxidant gene expression may confer vorinostat resistance. Further evaluation of vorinostat in AML/MDS is warranted...
  3. ncbi request reprint Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 109:3214-8. 2007
    ..Liposomal cytarabine given via intrathecal route concomitantly with systemic chemotherapy that crosses the blood-brain barrier such as high-dose MTX and cytarabine can result in significant neurotoxicity...
  4. ncbi request reprint A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas M D Anderson Cancer Center Houston, TX 77030, USA
    Leuk Lymphoma 48:283-9. 2007
    ..Median survival was 5 months (range, 2 - 20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP...
  5. ncbi request reprint Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia
    Yasuhiro Oki
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:899-906. 2007
    ..A Phase II study was performed on low-dose decitabine, a DNA methyltransferase inhibitor, in combination with imatinib in patients with CML in accelerated phase (AP) and myeloid blastic phase (BP)...
  6. ncbi request reprint Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
    Andres O Soriano
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2302-8. 2007
    ..VPA blood levels were higher in responders (P < .005). In conclusion, the combination studied is safe and has significant clinical activity. This clinical trial was registered at www.clinicaltrials.gov as no. NCT00326170...
  7. ncbi request reprint Biphenotypic acute leukaemia: a case series
    Ahmed Aribi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston TX 77030, USA
    Br J Haematol 138:213-6. 2007
    ..Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%...
  8. ncbi request reprint The role of decitabine in the treatment of myelodysplastic syndromes
    Ehab Atallah
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Expert Opin Pharmacother 8:65-73. 2007
    ..Ongoing studies are evaluating the activity and safety of the combination of decitabine with several histone deacetylase inhibitors and other indications. This article summarizes the experience in with decitabine in MDS...
  9. ncbi request reprint Effect of cytarabine and decitabine in combination in human leukemic cell lines
    Taichun Qin
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4225-32. 2007
    ..5-Aza-2'-deoxycytidine (DAC) is a cytosine analogue that inhibits DNA methylation and also has activity in myeloid leukemia. Therefore, we investigated combining these two drugs in human leukemia cell lines in vitro...
  10. ncbi request reprint Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Elias Jabbour
    Department of Leukemia and, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2991-5. 2007
    ..CAs occur in Ph-negative cells in a small percentage of patients with newly diagnosed CML treated with IM. In rare instances, these could reflect the emergence of a new malignant clone...
  11. ncbi request reprint Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia
    Ahmed Aribi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 109:1355-9. 2007
    ..Arsenic trioxide (ATO) is an effective agent for the salvage of patients with recurrent APL, and gemtuzumab ozogamicin (GO) has shown activity in patients with APL...
  12. ncbi request reprint Use of hypomethylating agents in myelodysplastic syndromes
    Ehab Atallah
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 5:544-52. 2007
    ..Here we summarize the experience of hypomethylating agents in myelodysplastic syndromes...
  13. ncbi request reprint PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2012-8. 2007
    ..PEG-IFN-alpha-2b is a pegylated IFN-alpha-2b with a significant advantage over nonpegylated form in that it is administered once a week...
  14. pmc Epigenetic therapy of leukemia: An update
    Nitin Jain
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Biochem Cell Biol 41:72-80. 2009
    ..In this review, we will focus on recent advances in epigenetic therapy in leukemia...
  15. ncbi request reprint Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Blood 101:3413-5. 2003
    ..The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses...
  16. ncbi request reprint Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Invest 23:635-42. 2005
    ..In this article, we provide a brief introduction to the field of histone deacetylation inhibition in cancer and review the most relevant clinical data so far published...
  17. ncbi request reprint Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone
    Apostolia M Tsimberidou
    Department of Leukemia, Unit 428, The University of Texas M D Anderson Cancer Center, Houston, Texas77030, USA
    Cancer 107:125-35. 2006
    ..The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or chemotherapy alone...
  18. ncbi request reprint A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Francis Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4628-35. 2006
    ..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
  19. ncbi request reprint A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia
    Tapan M Kadia
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 150:72-82. 2010
    ..The combination of vorinostat and idarubicin is generally tolerable and active in patients with advanced leukaemia and should be studied in the front-line setting...
  20. ncbi request reprint HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target
    Xin Han
    Department of Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 20:54-62. 2007
    ..05) and p21 (P<0.001) were expressed significantly more often in Ph+ pre-B ALL. HDM4 and HDM2 showed no correlation with Ph status. HDM4 expression in most cases of adult pre-B ALL suggests that HDM4 is a potential therapeutic target...
  21. pmc Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome
    Hagop Kantarjian
    The University of Texas M D Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:285-91. 2010
    ..Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that is different from cytarabine...
  22. ncbi request reprint Leukemia and lymphoma: what is the role for intrathecal prophylactic treatment in adults?
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Houston, TX 77030, USA
    Expert Rev Neurother 4:S25-31. 2004
    ..be applied to adult patients with leukemia? In addition and as an extension of the adult leukemia patient discussion, is there a role for intrathecal prophylaxis in patients with lymphoma, a population at risk for neoplastic meningitis?..
  23. ncbi request reprint Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes
    Francis J Giles
    The University of Texas, M D Anderson Cancer Center, Department of Leukemia, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Leuk Res 29:649-52. 2005
    ..There was no significant impact on CR rates, TTF, survival, or toxicity of adding an IL-11 regimen to IA induction in patients >/=50 years of age with AML...
  24. ncbi request reprint Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 11:7817-24. 2005
    ..A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease...
  25. ncbi request reprint Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer 112:837-45. 2008
    ..Response rates in chronic myeloid leukemia (CML) are now reported based on the cumulative incidence of a single-time best response. The study aim was to examine the significance of different response criteria for CML on imatinib therapy...
  26. ncbi request reprint A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens
    William Wierda
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:337-45. 2006
    ..The objective of the current analysis was to determine whether improvements in treatment have had an impact on survival for patients with CLL...
  27. ncbi request reprint Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    William Wierda
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:4070-8. 2005
    ..The purpose of this study was to improve the complete remission (CR) rate for previously treated patients and evaluate the quality of bone marrow response...
  28. doi request reprint Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Apostolia M Tsimberidou
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA
    J Clin Oncol 26:196-203. 2008
    ..We conducted a phase I-II trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) in these diseases...
  29. doi request reprint Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:981-9. 2008
    ..In summary, MGCD0103 was safe and had antileukemia activity that was mechanism based in patients with advanced leukemia...
  30. ncbi request reprint A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:1638-45. 2008
    ..4 months vs 5.8 months; P = .1). Clofarabine plus low-dose cytarabine has a higher response rate than clofarabine alone with comparable toxicity. This trial is registered at www.clinicaltrials.gov as no. NCT00088218...
  31. pmc Demethylating agents in myeloid malignancies
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Oncol 20:705-10. 2008
    ..It is proposed that hypomethylating agents work by inducing reexpression of epigenetically silenced genes. Here, we provide an up-to-date summary of the clinical experience with these drugs...
  32. ncbi request reprint Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:1287-92. 2004
    ....
  33. ncbi request reprint Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers
    Emile M Youssef
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:2411-7. 2004
    ..These findings indicate that silencing of TIG1 promoter by hypermethylation is common in human cancers and may contribute to the loss of retinoic acid responsiveness in some neoplastic cells...
  34. ncbi request reprint Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
    ..Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed...
  35. ncbi request reprint Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:656-64. 2002
    ..To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia...
  36. ncbi request reprint A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1234-41. 2003
    ....
  37. ncbi request reprint Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy
    Gloria N Mattiuzzi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:581-9. 2004
    ..A prospective historical control study evaluated the efficacy and safety of amphotericin B lipid complex (ABLC) in this patient population...
  38. doi request reprint Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor
    Wei Gang Tong
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Leuk Res 34:221-8. 2010
    ..In conclusion, JNJ-26481585 is a potent second-generation pan-HDAC inhibitor with activity in human leukemia, and it is currently in clinical development...
  39. pmc Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6330-7. 2009
    ..Incorporation of monoclonal antibodies directed against CD20 into frontline chemotherapy regimens warrants investigation...
  40. doi request reprint Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, U T MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 148:386-93. 2010
    ..These data further indicate that plasma may be a good target to evaluate for minimal residual disease using cCD52/cCD20 levels...
  41. pmc Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1133-7. 2007
    ..The comparative efficacy of these 2 forms of treatment in MDS is unknown. The objective of the current study was to compare the efficacy and toxicity profiles of decitabine and intensive chemotherapy in MDS...
  42. doi request reprint Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:504-10. 2009
    ....
  43. pmc Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate
    Yumin Hu
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 116:2732-41. 2010
    ..Such a combination strategy may be an effective therapeutic regimen and have potential clinical application in leukemia...
  44. ncbi request reprint Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77230 1402, USA
    J Clin Oncol 28:2755-60. 2010
    ..Efficacy and toxicity profile of orally administered clofarabine were evaluated in patients with higher-risk myelodysplastic syndrome (MDS)...
  45. ncbi request reprint The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy
    Yue Wei
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 16:3923-32. 2010
    ..We hypothesized, therefore, that combination of an HDACi with a proapoptotic agent, such as the Bcl-2 homology domain-3 mimetic GX15-070, could result in enhanced antileukemia activity...
  46. ncbi request reprint Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
    Alfonso Quintas-Cardama
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:248-55. 2007
    ..Homoharringtonine (HHT) is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis. Intravenous HHT has demonstrated activity in patients with chronic myeloid leukemia (CML) after failure with interferon...
  47. ncbi request reprint Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
    Hagop Kantarjian
    Department of Leukemia, Anderson Cancer Center, Houston, TX, USA
    Blood 102:2379-86. 2003
    ..03). This increased only in responders (median, 1.8-fold; P =.008) after the second clofarabine infusion. In summary, clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance...
  48. ncbi request reprint Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:2760-6. 2003
    ..c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated in the pathogenesis of myeloproliferative disorders (MPD)...
  49. ncbi request reprint Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:1722-7. 2003
    ..A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy...
  50. ncbi request reprint Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2167-76. 2002
    ..Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML)...
  51. ncbi request reprint Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia
    Lanlan Shen
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:4131-6. 2003
    ..02). Our results indicate that p57KIP2 is frequently methylated in adult patients with ALL, and that inactivation of a pathway composed of p73, p15, and p57KIP2 predicts for poor prognosis in Ph-negative patients...
  52. ncbi request reprint Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
    Jorge E Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:3794-800. 2003
    ..The 3-month cytogenetic response to imatinib mesylate refined the prognostic relevance of such studies in patients on imatinib mesylate therapy...
  53. ncbi request reprint Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
    Jorge Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:1692-7. 2003
    ..R115777 showed clinical activity in patients with CML and MF. The effect on VEGF needs to be further investigated to determine whether this might be a possible mechanism of action of R115777...
  54. ncbi request reprint Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3547-53. 2002
    ..04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML...
  55. ncbi request reprint Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 100:1590-5. 2002
    ..We conclude that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD...
  56. ncbi request reprint Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens
    Dushyant Verma
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:101-6. 2009
    ..Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children...
  57. doi request reprint Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:1933-52. 2008
    ..In patients with MDS, it was recently demonstrated that epigenetic therapy with hypomethylating agents improved survival. Much therapeutic progress has been witnessed in leukemia and MDS, and much more is expected to occur soon...
  58. ncbi request reprint Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2134-41. 2002
    ....
  59. ncbi request reprint Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:1050-6. 2003
    ..Troxacitabine has significant single-agent activity. This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan...
  60. ncbi request reprint Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:265-73. 2007
    ..In this study, the authors update their experience with decitabine in patients with MDS and analyze the cytogenetic response patterns and prognostic factors associated with decitabine therapy...
  61. ncbi request reprint Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1090-8. 2006
    ....
  62. ncbi request reprint Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
    Stefan Faderl
    Department of Leukemia, Box 428, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 105:940-7. 2005
    ..The combination of clofarabine with ara-C is safe and active. Cellular pharmacology data support the biochemical modulation strategy...
  63. ncbi request reprint Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal
    Jorge E Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 106:1306-15. 2006
    ....
  64. ncbi request reprint Phase I study of bortezomib in refractory or relapsed acute leukemias
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:3371-6. 2004
    ..The in vitro evidence of antileukemia and transient hematological improvements observed in some patients warrants further investigation of bortezomib in acute leukemias, probably in combination with other agents...
  65. ncbi request reprint Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:1430-7. 2003
    ..The objective of the current study was to evaluate the benefit of adding imatinib to the treatment sequence of patients with early chronic phase Ph-positive CML who received interferon alpha (IFN)-based regimens as frontline therapy...
  66. ncbi request reprint Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    Elihu Estey
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe, Box 428, Houston, 77030, USA
    Blood 107:3469-73. 2006
    ..ATRA plus ATO may serve as an alternative to chemotherapy in low-risk untreated APL (eg, in older patients) and, when combined with GO, may improve outcome in high-risk patients...
  67. ncbi request reprint Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:1105-13. 2003
    ....
  68. ncbi request reprint A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:2908-17. 2004
    ..As alkylating agents are important antileukemia drugs, a Phase I and pharmacokinetic study of VNP40101M was conducted in patients with refractory or relapsed leukemias or poor-risk myelodysplastic syndromes (MDS)...
  69. pmc Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 34:752-6. 2010
    ..017). Overall, patients with mutated FLT3 had a shorter survival from the time of relapse compared to those with FLT3-WT (P<0.001). The adverse prognostic impact of FLT3 mutations appears to persist beyond the initial treatment...
  70. pmc Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:5746-51. 2009
    ..Outcome of patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) with chromosome 5 and 7 abnormalities (excluding del 5[q]) has been poor, with <10% of patients alive at 2 years...
  71. doi request reprint Progress in myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S286-92. 2009
    ....
  72. pmc Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
    Deborah A Thomas
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3880-9. 2010
    ....
  73. pmc Characteristics of pericardial effusions in patients with leukemia
    Keeran Sampat
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:2366-71. 2010
    ..To study the characteristics and treatment relationships of PEs in patients with leukemia, the authors retrospectively analyzed a cohort of patients with leukemia evaluated at a single center...
  74. pmc Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia
    Koyu Hoshino
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Leuk Res 33:1361-6. 2009
    ..53). Overall, our results indicate that JUNB expression is downregulated in advanced phase CML through a mechanism independent from DNA methylation...
  75. pmc Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 28:1856-62. 2010
    ..Plasma inhibitory assay demonstrated an on-target effect on FLT3 kinase activity. CONCLUSION Sorafenib can be safely combined with chemotherapy, produces a high CR rate in FLT3-mutated patients, and inhibits FLT3 signaling...
  76. ncbi request reprint Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Fabio P S Santos
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 150:303-12. 2010
    ..Further studies are required to determine whether there might be a minimum adequate dose of these agents...
  77. ncbi request reprint Future directions for the use of hypomethylating agents
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 42:S50-9. 2005
    ..This review discusses the potential use of methylation reversing agents in the treatment of solid tumors and in benign hematologic disorders along with the rationale for combination therapies using hypomethylating agents...
  78. ncbi request reprint Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Box 428, Houston, TX 77030, USA
    Leuk Res 27:1077-83. 2003
    ..Based on these clinical, pharmacokinetic, and pharmacodynamic data, Triapine warrants further study in patients with hematologic malignancies...
  79. ncbi request reprint Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2636-42. 2003
    ..This was most likely because approximately 90% of patients receiving IFN-alpha plus ara-C changed to imatinib therapy after a median of 8 months into therapy...
  80. ncbi request reprint Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1351-61. 2008
    ....
  81. ncbi request reprint Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 109:52-7. 2007
    ..We conclude that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS...
  82. ncbi request reprint A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Haematologica 87:804-7. 2002
    ..We report the results of a phase I study of dose escalation of idarubicin with amifostine and high-dose ara-C in patients with relapsed or refractory AML or myelodysplastic syndrome (MDS)...
  83. ncbi request reprint Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:2341-51. 2008
    ..Combination therapies that augment the epigenetic effect of decitabine will likely improve responses and extend its use for the treatment of other malignancies...
  84. ncbi request reprint RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis
    Yanis A Boumber
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA
    Cancer Res 67:1997-2005. 2007
    ..In MDS, RIL methylation is a marker of adverse prognosis independent of chromosome 5 and 7 deletions. Our data suggest that RIL is a good candidate TSG silenced by hypermethylation in cancer...
  85. ncbi request reprint Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 104:1979-88. 2004
    ..0001); the survival advantage was confirmed by multivariate analysis (hazard ratio, 0.19; P <.0001)...
  86. ncbi request reprint Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature
    Apostolia Maria Tsimberidou
    Department of Leukemia, UT MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 28:657-60. 2004
    ..It appears that there is no in vivo interaction between imatinib and highly active anti-retroviral therapy (HAART) and these drugs can be concurrently administered with safety to patients with CML and AIDS...
  87. ncbi request reprint Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2000-6. 2007
    ....
  88. pmc Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
    Blanca Sanchez-Gonzalez
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 108:1174-82. 2006
    ..Of importance, the cellular and molecular effects observed were independent of the sequence used. In summary, the combination of an anthracycline with an HDACI should have significant clinical activity in patients with leukemia...
  89. ncbi request reprint Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:6615-24. 2005
    ..A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...
  90. ncbi request reprint Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
    ..Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens...
  91. ncbi request reprint Cytoprotection in acute myelogenous leukemia (AML) therapy
    Dolores Grosso
    Thomas Jefferson Health System, Blood and Marrow Transplant Program, Philadelphia, PA 19107, USA
    Semin Oncol 31:67-73. 2004
    ..Currently, phase II studies are ongoing on a national basis to evaluate the efficacy of this regimen...
  92. ncbi request reprint Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
    Susan O'Brien
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 98:888-93. 2003
    ....
  93. ncbi request reprint Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
    Apostolia Tsimberidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1481-7. 2003
    ....
  94. ncbi request reprint Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
    Apostolia M Tsimberidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1711-20. 2003
    ..A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) in these patients...
  95. ncbi request reprint Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies
    Apostolia Maria Tsimberidou
    Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston 77030, USA
    Leuk Res 28:991-4. 2004
    ..5 years after lipo-ATRA therapy and was successfully treated with the sequence of A2O3, ATRA, and GO and we summarize our experience with patients with isolated extramedullary relapse in APL...
  96. ncbi request reprint Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:813-22. 2006
    ..The recommended phase II regimen is Triapine 105 mg/m2/day followed by ara-C 600 mg/m2/day for 5 consecutive days every 3-6 weeks...
  97. ncbi request reprint Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
    Yesid Alvarado
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Cancer Chemother Pharmacol 51:87-90. 2003
    ..A combination of an anthracycline and cytarabine (ara-C) is the core of most AML induction regimens. We conducted a pilot study of Mylotarg combined with idarubicin and ara-C in patients with refractory or relapsed AML...
  98. ncbi request reprint Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome
    Francis Giles
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Acta Haematol 108:164-7. 2002
  99. ncbi request reprint Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
    Apostolia Tsimberidou
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Leuk Res 27:893-7. 2003
    ..CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML...
  100. doi request reprint Relapse and death during first remission in acute myeloid leukemia
    Masamitsu Yanada
    Haematologica 93:633-4. 2008
  101. ncbi request reprint Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
    Jorge Medina
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:1905-11. 2003
    ..This phenomenon is different from true clonal evolution in that the additional cytogenetic abnormality occurs in Ph-negative cells...